Search results for "locoregional"

showing 10 items of 14 documents

Hydrodynamic IL10 Gene Transfer in Human Colon: Results from an "EX VIVO" Study with Potential Clinical Application in Crohn's Disease.

2017

Background: The aim of this work is to evaluate the efficacy of hydrodynamic venous IL10 gene delivery to "ex vivo" human colon segments and to determine its potential interest in Crohn's disease treatment. Methods: Twenty human colon segments were obtained from surgical resections. Hydrodynamic transfection through the main vein of the pedicle with 50 mL of hIL10 plasmid (20 mu g/mL) solution was performed on 13 of them. Tissue sections were cultured and DNA, RNA, and protein copies were determined after 1, 2, and 4 days. Data obtained were compared with 6 nontransfected specimens. Finally, 1 specimen was injected with gold nanoparticles, and their distribution was examined under electron …

0301 basic medicineColoninterleukin-10Metal NanoparticlesGene deliverylocoregionalTranslational Research Biomedical03 medical and health scienceschemistry.chemical_compound0302 clinical medicineCrohn Diseaseinflammatory bowel diseaseSubmucosamedicineImmunology and AllergyHumansGenehydrodynamicChemistryGastroenterologyGene Transfer TechniquesRNATransfectionGenetic Therapygene therapyMolecular biologyInterleukin-10Interleukin 10030104 developmental biologymedicine.anatomical_structureHydrodynamics030211 gastroenterology & hepatologyGoldDNAEx vivoInflammatory bowel diseases
researchProduct

Buccal drug delivery: what's new and what does the future hold?

2014

The buccal mucosa is the stratified squamous epithelial tissue inside lining of the cheeks. It is a favorable site of drug absorption since the tissue is non-keratinized, relatively immobile and strongly supplied with blood by a dense capillary-vessel network; moreover, it is highly tolerant to allergens, resistant to potentially harmful agents and has a relatively low enzymatic activity. The tissue consents quick onset of effect, offers an easily accessible and generally well-accepted site for drug delivery, is a useful route of administration in patients in an unconscious state (e.g., when swallowing is impaired), and is suitable for retentive dosage forms of administration. Buccal mucosa…

3003Drugmedia_common.quotation_subjectChemistry PharmaceuticalPharmaceutical ScienceDentistryPharmacologyDosage formRoute of administrationDrug Delivery SystemsPharmacokineticsMucositisMedicineAnimalsHumansBuccal dosage formmedia_commonDosage FormsDrug Carriersbusiness.industryLocoregional/systemic treatmentMedicine (all)Mouth MucosaAdministration BuccalTransmucosal deliveryBuccal administrationmedicine.diseaseBioavailabilityPharmaceutical PreparationsSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoDrug deliveryBuccal mucosaDiffusion of InnovationbusinessForecastingTherapeutic delivery
researchProduct

5-Fluororacile-loaded matrix tablets for locoregional delivery: effects on a three-dimensional culture model of primary oral squamous cell carcinoma

2012

5-Fluorouracil Locoregional drug delivery Oral squamous cell carcinoma Buccal tablets 3D oral outgrowths
researchProduct

The Intention-to-Treat Effect of Bridging Treatments in the Setting of Milan Criteria–In Patients Waiting for Liver Transplantation

2019

In patients with hepatocellular carcinoma (HCC) meeting the Milan criteria (MC), the benefit of locoregional therapies (LRTs) in the context of liver transplantation (LT) is still debated. Initial biases in the selection between treated and untreated patients have yielded conflicting reported results. The study aimed to identify, using a competing risk analysis, risk factors for HCC-dependent LT failure, defined as pretransplant tumor-related delisting or posttransplant recurrence. The study was registered at www.clinicaltrials.gov (identification number NCT03723304). In order to offset the initial limitations of the investigated population, an inverse probability of treatment weighting (IP…

Ablation TechniquesGraft RejectionMaleTime FactorsHepatocellular carcinomaIMPACTmedicine.medical_treatmentSettore MED/18 - CHIRURGIA GENERALEintent to treatLOCOREGIONAL THERAPYKaplan-Meier Estimate030230 surgeryLiver transplantationLIVER TRANSPLANTATION HEPATOCELLULAR CARCINOMA RISK FACTORS OUTCOME PROGNOSTIC SCOREGastroenterologyLiver disease0302 clinical medicineRisk FactorsHEPATOCELLULAR-CARCINOMAHepatocellular carcinoma liver transplantation risk factors intent to treat prognostic score waiting listeducation.field_of_studyLiver NeoplasmsAge FactorsDEATHwaiting listMiddle AgedCANCERprognostic scoreIntention to Treat AnalysisTIMETreatment OutcomeHepatocellular carcinomaDisease ProgressionSURVIVAL030211 gastroenterology & hepatologyFemalemedicine.symptommedicine.medical_specialtyCarcinoma HepatocellularWaiting ListsALPHA-FETOPROTEINPopulationMilan criteriamRECISTRisk AssessmentLesionalpha-fetoprotein03 medical and health sciencesSex FactorsInternal medicinePreoperative CaremedicineHumansHepatology; gastroenterology; hepatocelluar cancer; locoregional therapieseducationRECURRENCEOUTCOMETransplantationLiver transplantationIntention-to-treat analysisHepatologybusiness.industryHEPATOCELLULAR-CARCINOMA; ALPHA-FETOPROTEIN; LOCOREGIONAL THERAPY; RECURRENCE; CANCER; MODEL; TIME; SURVIVAL; IMPACT; DEATHlocoregional therapymedicine.diseaseSettore MED/18Liver TransplantationMODELhepatocellular cancerTumor progressionSurgerybusinessFollow-Up Studies
researchProduct

5-Fluorouracil Buccal Tablets for Locoregional Chemotherapy of Oral Squamous Cell Carcinoma: Formulation, Drug Release and Histological Effects on Re…

2010

5-Fluorouracil (5-FU) is currently used for treatment of oral squamous cell carcinoma (OSCC). 5-FU is given by i.v. although the systemic administration is associated with severe toxic effects and no topical formulations of 5-FU for buccal drug delivery have been reported. In this study we would report the development of buccal tablets suitable for direct application of low-doses of 5-FU on cancer lesions. The topical administration could be effective on tumor area while systemic undesired side effects are avoided. Preliminarily, the limited tendency of 5-FU to cross the buccal tissue was established using reconstituted human oral epithelium (RHOE, in vitro) and porcine buccal mucosa (ex vi…

DrugAntimetabolites AntineoplasticPathologymedicine.medical_specialtySwineChemistry PharmaceuticalDrug Compounding5-Fluorouracilmedia_common.quotation_subjectPharmaceutical ScienceApoptosisSettore MED/08 - Anatomia PatologicaLocoregional drug deliveryOral Squamous Cell CarcinomaPermeabilityTissue Culture TechniquesDrug Delivery SystemsSettore MED/28 - Malattie OdontostomatologicheCarcinomaAnimalsHumansMedicinemedia_commonbusiness.industryMouth MucosaAdministration BuccalCancerBuccal administrationmedicine.diseaseReconstituted Human Oral Epitheliumstomatognathic diseasesSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoFluorouracilDrug deliveryCarcinoma Squamous CellSystemic administrationMouth NeoplasmsFluorouracilPorcine buccal mucosaBuccal tabletsbusinessEx vivoTabletsmedicine.drugCurrent Drug Delivery
researchProduct

Aloin delivery on buccal mucosa: ex vivo studies and design of a new locoregional dosing system

2014

Context: Chemoprevention of potential malignant disorders or cancerous lesions that affect oral mucosae requires extended duration of treatment. Locoregional delivery of natural products could represent a promising strategy for this purpose. Objective: To investigate the aptitude of aloin to permeate through, or accumulate in, the buccal mucosa and to develop a new prolonged oro-mucosal drug delivery system. Materials and Methods: Permeation/accumulation of aloin from Curacao Aloe (containing 50% barbaloin) was evaluated ex vivo, using porcine buccal mucosa as the most useful model to simulate human epithelium. Oro-mucosal matrix tablets were prepared by dispersing aloin (10% w/w) in Eudrag…

DrugEmodinPolymersSwinemedia_common.quotation_subjectChemistry PharmaceuticalAcrylic ResinsPharmaceutical ScienceDentistryAloinPharmacologyFriabilityPermeabilityBarbaloin buccal tablets aloin matrix tablets oro-mucosal delivery locoregional drug delivery buccal mucosa.chemistry.chemical_compoundDrug Delivery SystemsSettore MED/28 - Malattie OdontostomatologicheDrug DiscoverymedicineAnimalsDosingAloemedia_commonPharmacologybusiness.industryOrganic ChemistryMouth MucosaAdhesivenessReproducibility of ResultsPermeationDrug LiberationchemistrySettore CHIM/09 - Farmaceutico Tecnologico ApplicativoDrug deliverySwellingmedicine.symptombusinessEx vivoTablets
researchProduct

Charting the Path Forward for Risk Prediction in Liver Transplant for Hepatocellular Carcinoma: International Validation of HALTHCC Among 4,089 Patie…

2020

Prognosticating outcomes in liver transplant (LT) for hepatocellular carcinoma (HCC) continues to challenge the field. Although Milan Criteria (MC) generalized the practice of LT for HCC and improved outcomes, its predictive character has degraded with increasing candidate and oncological heterogeneity. We sought to validate and recalibrate a previously developed, preoperatively calculated, continuous risk score, the Hazard Associated with Liver Transplantation for Hepatocellular Carcinoma (HALTHCC), in an international cohort. From 2002 to 2014, 4,089 patients (both MC in and out [25.2%]) across 16 centers in North America, Europe, and Asia were included. A continuous risk score using pre-…

OncologyMalemedicine.medical_specialtyCarcinoma HepatocellularSettore MED/18 - CHIRURGIA GENERALEmedicine.medical_treatmentInternational CooperationPROGNOSTIC SCORETumor burdengastroenterologyLIVER TRANSPLANTATION HEPATOCELLULAR CARCINOMA RISK FACTORS OUTCOME PROGNOSTIC SCORELiver transplantationMilan criteriaRisk AssessmentLiver diseaseInternal medicinemedicineHumansHepatology; gastroenterology; hepatocelluar cancer; locoregional therapiesHEPATOCELLULAR CARCINOMARetrospective StudiesOUTCOMEFramingham Risk ScoreHepatologybusiness.industryPoorly differentiatedLiver Neoplasmshepatocelluar cancerMiddle Agedmedicine.diseasePrognosisSettore MED/18Liver TransplantationRISK FACTORSHepatocellular carcinomaCohortlocoregional therapiesFemalebusinessHepatology (Baltimore, Md.)References
researchProduct

Gastric Cancer: Locoregional Disease

2021

Gastric cancer (GC) is still a worldwide major leading cause of cancer death which shows large geographical differences. Despite an overall decline in incidence and mortality over the last decades, GC remains a poor prognosis disease since patients often present with advanced stage of disease. A large number of risk factors have been associated with GC. Thus, prevention (environment and lifestyle factors) and early diagnosis may be the most promising strategies for cancer control and key strategies to reduce mortality. Surgical resection remains the main form of curative treatment whenever feasible. Endoscopic approaches have been used as valid alternatives to surgery for selected patients.…

Oncologymedicine.medical_specialtybusiness.industryIncidence (epidemiology)Standard treatmentLocally advancedCancerDiseasemedicine.diseasePrimary tumorLocoregional diseaseInternal medicineEpidemiologymedicinebusiness
researchProduct

Pressurized intraperitoneal aerosol chemotherapy with cisplatin and doxorubicin or oxaliplatin for peritoneal metastasis from pancreatic adenocarcino…

2020

Background: Systemic chemotherapy for pancreatic adenocarcinoma (PDAC) and cholangiocarcinoma (CC) with peritoneal metastases (PM) is affected by several pharmacological shortcomings and low clinical efficacy. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is expected to maximize exposure of peritoneal nodules to antiblastic agents. This study aims to evaluate safety and efficacy of PIPAC for PM of PDAC and CC origin. Methods: This is a retrospective analysis of consecutive PDAC and CC cases with PM treated with PIPAC at two European referral centers for peritoneal disease. We prospectively recorded from August 2016 to May 2019 demographic, clinical, surgical, and oncological data…

Peritoneal metastasismedicine.medical_treatmentSettore MED/18 - CHIRURGIA GENERALEpancreatic cancerPIPACcarcinomatosislcsh:RC254-282Pancreatic cancerMedicineDoxorubicincarcinomatosiOriginal ResearchCisplatinChemotherapybusiness.industrySystemic chemotherapyperitoneal metastaseaerosol chemotherapymedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensdigestive system diseasesOxaliplatinperitoneal metastasesOncologyCancer researchlocoregional chemotherapyAdenocarcinomaPIPAC.businesscholangiocarcinomamedicine.drugTherapeutic Advances in Medical Oncology
researchProduct

Immunotherapy-Based Treatments of Hepatocellular Carcinoma: AJR Expert Panel Narrative Review

2022

The advent of immunotherapy for patients with hepatocellular carcinoma (HCC) has changed the treatment landscape and conferred a survival benefit on patients with advanced HCC, who typically have a very poor prognosis. The most pronounced improvements in response, as documented by standardized response criteria based on CT or MRI, have been achieved when immunotherapy is combined with other systemic or locoregional therapies. Immune checkpoint inhibitor treatments result in unique patterns on CT and MRI that challenge the application of conventional response criteria such as RECIST, modified RECIST, and European Association for the Study of the Liver criteria. Thus, newer criteria have been…

RECISTlocoregional therapyimmune checkpoint inhibitorRadiology Nuclear Medicine and imaginghepatocellular carcinomaimmunotherapyGeneral Medicinemultikinase inhibitormRECISTCTMRIAmerican Journal of Roentgenology
researchProduct